522 related articles for article (PubMed ID: 24445294)
1. Commentary on "integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer." Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, Jäger N, Gu L, Bogatyrova O, Stütz AM, Claus R, Eils J, Eils R, Gerhäuser C, Huang PH, Hutter B, Kabbe R, Lawerenz C, Radomski S, Bartholomae CC, Fälth M, Gade S, Schmidt M, Amschler N, Haß T, Galal R, Gjoni J, Kuner R, Baer C, Masser S, von Kalle C, Zichner T, Benes V, Raeder B, Mader M, Amstislavskiy V, Avci M, Lehrach H, Parkhomchuk D, Sultan M, Burkhardt L, Graefen M, Huland H, Kluth M, Krohn A, Sirma H, Stumm L, Steurer S, Grupp K, Sültmann H, Sauter G, Plass C, Brors B, Yaspo ML, Korbel JO, Schlomm T, Genome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.: Cancer Cell 2013;23(2):159-70.
Olumi AF
Urol Oncol; 2014 Feb; 32(2):212. PubMed ID: 24445294
[TBL] [Abstract][Full Text] [Related]
2. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer.
Weischenfeldt J; Simon R; Feuerbach L; Schlangen K; Weichenhan D; Minner S; Wuttig D; Warnatz HJ; Stehr H; Rausch T; Jäger N; Gu L; Bogatyrova O; Stütz AM; Claus R; Eils J; Eils R; Gerhäuser C; Huang PH; Hutter B; Kabbe R; Lawerenz C; Radomski S; Bartholomae CC; Fälth M; Gade S; Schmidt M; Amschler N; Haß T; Galal R; Gjoni J; Kuner R; Baer C; Masser S; von Kalle C; Zichner T; Benes V; Raeder B; Mader M; Amstislavskiy V; Avci M; Lehrach H; Parkhomchuk D; Sultan M; Burkhardt L; Graefen M; Huland H; Kluth M; Krohn A; Sirma H; Stumm L; Steurer S; Grupp K; Sültmann H; Sauter G; Plass C; Brors B; Yaspo ML; Korbel JO; Schlomm T
Cancer Cell; 2013 Feb; 23(2):159-70. PubMed ID: 23410972
[TBL] [Abstract][Full Text] [Related]
3. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
4. 32nd International Austrian Winter Symposium : Zell am See, the Netherlands. 20-23 January 2016.
Langsteger W; Rezaee A; Loidl W; Geinitz HS; Fitz F; Steinmair M; Broinger G; Pallwien-Prettner L; Beheshti M; Imamovic L; Beheshti M; Rendl G; Hackl D; Tsybrovsky O; Steinmair M; Emmanuel K; Moinfar F; Pirich C; Langsteger W; Bytyqi A; Karanikas G; Mayerhöfer M; Koperek O; Niederle B; Hartenbach M; Beyer T; Herrmann K; Czernin J; Rausch I; Rust P; DiFranco MD; Lassen M; Stadlbauer A; Mayerhöfer ME; Hartenbach M; Hacker M; Beyer T; Binzel K; Magnussen R; Wei W; Knopp MU; Flanigan DC; Kaeding C; Knopp MV; Leisser A; Nejabat M; Hartenbach M; Kramer G; Krainer M; Hacker M; Haug A; Lehnert W; Schmidt K; Kimiaei S; Bronzel M; Kluge A; Wright CL; Binzel K; Zhang J; Wuthrick E; Maniawski P; Knopp MV; Blaickner M; Rados E; Huber A; Dulovits M; Kulkarni H; Wiessalla S; Schuchardt C; Baum RP; Knäusl B; Georg D; Bauer M; Wulkersdorfer B; Wadsak W; Philippe C; Haslacher H; Zeitlinger M; Langer O; Bauer M; Feldmann M; Karch R; Wadsak W; Zeitlinger M; Koepp MJ; Asselin MC; Pataraia E; Langer O; Zeilinger M; Philippe C; Dumanic M; Pichler F; Pilz J; Hacker M; Wadsak W; Mitterhauser M; Nics L; Steiner B; Hacker M; Mitterhauser M; Wadsak W; Traxl A; Wanek T; Kryeziu K; Mairinger S; Stanek J; Berger W; Kuntner C; Langer O; Mairinger S; Wanek T; Traxl A; Krohn M; Stanek J; Filip T; Sauberer M; Kuntner C; Pahnke J; Langer O; Svatunek D; Denk C; Wilkovitsch M; Wanek T; Filip T; Kuntner-Hannes C; Fröhlich J; Mikula H; Denk C; Svatunek D; Wanek T; Mairinger S; Stanek J; Filip T; Fröhlich J; Mikula H; Kuntner-Hannes C; Balber T; Singer J; Fazekas J; Rami-Mark C; Berroterán-Infante N; Jensen-Jarolim E; Wadsak W; Hacker M; Viernstein H; Mitterhauser M; Denk C; Svatunek D; Sohr B; Mikula H; Fröhlich J; Wanek T; Kuntner-Hannes C; Filip T; Pfaff S; Philippe C; Mitterhauser M; Hartenbach M; Hacker M; Wadsak W; Wanek T; Halilbasic E; Visentin M; Mairinger S; Stieger B; Kuntner C; Trauner M; Langer O; Lam P; Aistleitner M; Eichinger R; Artner C; Eidherr H; Vraka C; Haug A; Mitterhauser M; Nics L; Hartenbach M; Hacker M; Wadsak W; Kvaternik H; Müller R; Hausberger D; Zink C; Aigner RM; Cossío U; Asensio M; Montes A; Akhtar S; Te Welscher Y; van Nostrum R; Gómez-Vallejo V; Llop J; VandeVyver F; Barclay T; Lippens N; Troch M; Hehenwarter L; Egger B; Holzmannhofer J; Rodrigues-Radischat M; Pirich C; Pötsch N; Rausch I; Wilhelm D; Weber M; Furtner J; Karanikas G; Wöhrer A; Mitterhauser M; Hacker M; Traub-Weidinger T; Cassou-Mounat T; Balogova S; Nataf V; Calzada M; Huchet V; Kerrou K; Devaux JY; Mohty M; Garderet L; Talbot JN; Stanzel S; Pregartner G; Schwarz T; Bjelic-Radisic V; Liegl-Atzwanger B; Aigner R; Stanzel S; Quehenberger F; Aigner RM; Marković AK; Janković M; Jerković VM; Paskaš M; Pupić G; Džodić R; Popović D; Fornito MC; Familiari D; Koranda P; Polzerová H; Metelková I; Henzlová L; Formánek R; Buriánková E; Kamínek M; Thomson WH; Lewis C; Thomson WH; O'Brien J; James G; Notghi A; Huber H; Stelzmüller I; Wunn R; Mandl M; Fellner F; Lamprecht B; Gabriel M; Fornito MC; Leonardi G; Thomson WH; O'Brien J; James G; Hudzietzová J; Sabol J; Fülöp M
EJNMMI Res; 2016 Apr; 6(Suppl 1):32. PubMed ID: 27090254
[TBL] [Abstract][Full Text] [Related]
5. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T
Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038
[TBL] [Abstract][Full Text] [Related]
6. Emerging biological observations in prostate cancer.
Shah S; Small E
Expert Rev Anticancer Ther; 2010 Jan; 10(1):89-101. PubMed ID: 20014889
[TBL] [Abstract][Full Text] [Related]
7. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
[TBL] [Abstract][Full Text] [Related]
8. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.
Perner S; Rupp NJ; Braun M; Rubin MA; Moch H; Dietel M; Wernert N; Jung K; Stephan C; Kristiansen G
Int J Cancer; 2013 Feb; 132(4):807-12. PubMed ID: 22821757
[TBL] [Abstract][Full Text] [Related]
9. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
10. Commentary on "Integrative clinical genomics of advanced prostate cancer". Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.Cell. 21 May 2015;161(5):1215-1228.
Freedland SJ; Aronson WJ
Urol Oncol; 2017 Aug; 35(8):535. PubMed ID: 28623072
[TBL] [Abstract][Full Text] [Related]
11. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
13. Retention of Interstitial Genes between
Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
[No Abstract] [Full Text] [Related]
14. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.
Kolar Z; Burdova A; Jamaspishvili T; Bouchal J; Kucerova R; Bienova M; Kral M; Student V
Neoplasma; 2014; 61(1):9-16. PubMed ID: 24195515
[TBL] [Abstract][Full Text] [Related]
15. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
[TBL] [Abstract][Full Text] [Related]
16. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.
Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Selvarajah S; Evans AJ; Zielenska M; Squire JA
Neoplasia; 2006 Jun; 8(6):465-9. PubMed ID: 16820092
[TBL] [Abstract][Full Text] [Related]
17. Commentary on: "Inherited DNA-repair gene mutations in men with metastatic prostate cancer." Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.
Lee BH
Urol Oncol; 2017 Sep; 35(9):575-576. PubMed ID: 28789927
[TBL] [Abstract][Full Text] [Related]
18. Commentary on "Inherited DNA-repair gene mutations in men with metastatic prostate cancer". Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016;375(5):443-53.
Freedland SJ; Aronson WJ
Urol Oncol; 2017 Aug; 35(8):536-537. PubMed ID: 28623070
[TBL] [Abstract][Full Text] [Related]
19. Genetic, Environmental, and Nuclear Factors Governing Genomic Rearrangements.
Ramanand SG; Mani RS
Adv Exp Med Biol; 2019; 1210():57-66. PubMed ID: 31900904
[TBL] [Abstract][Full Text] [Related]
20. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
